Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.46 |
| ▸ | EGFR | P00533 | 5/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | AGXT | P21549 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1888995 | 0.88 | CYP19A1 (0.44) | EGFRERBB2ALDH1A1GAAHSD17B10 | |
| SCHEMBL265696 | 0.83 | PTGS2 (0.46) | MMP2ALDH1A1PTGS2AKR1C3AKR1C2 | |
| SCHEMBL29595880 | 0.83 | PTGS2 (0.46) | MMP2ALDH1A1PTGS2AKR1C3AKR1C2 | |
| SCHEMBL17737834 | 0.81 | KMT2A (0.46) | TAAR1ALDH1A1GAAHSD17B10IDO1 | |
| SCHEMBL9200966 | 0.79 | TAAR1 (0.60) | TAAR1ALDH1A1IDO1AGXT | |
| SCHEMBL1889801 | 0.79 | MAOB (0.67) | MMP2ALDH1A1 | |
| SCHEMBL29411715 | 0.78 | ALDH1A1 (0.46) | ALDH1A1GAAHSD17B10DRD2NR1H2 | |
| SCHEMBL533931 | 0.78 | ALDH1A1 (0.46) | ALDH1A1GAAHSD17B10DRD2NR1H2 | |
| SCHEMBL7054313 | 0.76 | ALDH1A1 (0.47) | ALDH1A1GAAHSD17B10DRD2 | |
| SCHEMBL8233359 | 0.76 | ALDH1A1 (0.47) | ALDH1A1GAAHSD17B10DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112135-A1 | Imidazo [1,2-A] Pyridine Compounds | WYETH LLC | 2011-05-12 | — | — | US | disclosed |
| CN-101945871-A | Imidazo [1,2-a] pyridine compounds | WYETH LLC | 2011-01-12 | — | — | CN | disclosed |
| EP-2231660-A1 | IMIDAZO [1,2-A] PYRIDINE COMPOUNDS | Wyeth LLC (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009086123-A1 | IMIDAZO [1,2-A] PYRIDINE COMPOUNDS | WYETH (US) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112135-A1 | Imidazo [1,2-A] Pyridine Compounds | NR1H2, NR1H3, NR1H4 | TAAR1 101/4885EGFR 247/4885ERBB2 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.